The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Maychuk D.Yu.

S.N. Fedorov National Medical Research Center “MNTK “Eye Microsurgery”

Yani E.V.

Helmholtz National Medical Research Center of Eye Diseases

Brzheskiy V.V.

Saint Petersburg State Pediatric Medical University

Grishina E.E.

Moscow Regional Clinical Research Institute named after M.F. Vladimirsky (MONIKI)

Drozdova E.A.

South-Ural State Medical University

Maychuk N.V.

OOO Medical Center “Hyppocratus“

Panova I.E.

Saint Petersburg branch of S.N. Fedorov National Medical Research Center “MNTK “Eye Microsurgery”

Safonova T.N.

Krasnov Research Institute of Eye Diseases

The place of ciclosporin A cationic emulsion 0.1% in the therapy of xerophthalmia

Authors:

Maychuk D.Yu., Yani E.V., Brzheskiy V.V., Grishina E.E., Drozdova E.A., Maychuk N.V., Panova I.E., Safonova T.N.

More about the authors

Journal: Russian Annals of Ophthalmology. 2024;140(2): 102‑111

DOI: 10.17116/oftalma2024140021102

Read: 2092 times

Download PDF (RU)
Contact the author
Table of contents

THE PLACE OF CICLOSPORIN A CATIONIC EMULSION 0.1% IN THE THERAPY OF XEROPHTHALMIA
THE PLACE OF CICLOSPORIN A CATIONIC EMULSION 0.1% IN THE THERAPY OF XEROPHTHALMIA

To cite this article:

Maychuk DYu, Yani EV, Brzheskiy VV, et al. . The place of ciclosporin A cationic emulsion 0.1% in the therapy of xerophthalmia. Russian Annals of Ophthalmology. 2024;140(2):102‑111. (In Russ.)
https://doi.org/10.17116/oftalma2024140021102

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Evaluation of the effi­cacy of anti­fibrotic drugs on cell cultures in Salzmann’s nodu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):80-89
Microbiota of the ocular surface in children with myopia. Russian Annals of Ophthalmology. 2025;(3):5-12
Evaluation of the effi­ciency of combined pharmaco-physiotherapy in patients with dry eye syndrome. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6-2):91-95
Abstract:

Dry eye disease (DED) is pathogenetically based on inflammation of the ocular surface. A step-by-step approach to DED treatment involves early initiation of anti-inflammatory therapy, including instillation of cyclosporine A (CsA). However, recommendations for the use of topical CsA in clinical practice are limited. This article presents an expert consensus on practical recommendations for the management of patients with DED, including indications, time of initiation and duration of CsA therapy, comparison of CsA forms currently registered in the Russian Federation, as well as issues of patient education.

Keywords:

dry eye disease
cyclosporin A
Ikervis
ocular surface
cationic emulsion

Authors:

Maychuk D.Yu.

S.N. Fedorov National Medical Research Center “MNTK “Eye Microsurgery”

Yani E.V.

Helmholtz National Medical Research Center of Eye Diseases

Brzheskiy V.V.

Saint Petersburg State Pediatric Medical University

Grishina E.E.

Moscow Regional Clinical Research Institute named after M.F. Vladimirsky (MONIKI)

Drozdova E.A.

South-Ural State Medical University

Maychuk N.V.

OOO Medical Center “Hyppocratus“

Panova I.E.

Saint Petersburg branch of S.N. Fedorov National Medical Research Center “MNTK “Eye Microsurgery”

Safonova T.N.

Krasnov Research Institute of Eye Diseases

Received:

07.03.2024

Accepted:

22.03.2024

Close metadata

References:

  1. Klokova OA, Damashauskas RO, Geidenrich MS. Ocular surface treatment in dry eye patients before corneal refractive surgery. Russian Journal of Clinical Ophthalmology = Klinicheskaya oftal’mologiya. 2020;20(4):180-186 (In Russ.). https://doi.org/10.32364/2311-7729-2020-20-4-180-186
  2. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, Viso E, Vitale S, Jones L. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334-365.  https://doi.org/10.1016/j.jtos.2017.05.003
  3. Brzhesky VV, Kalinina IV, Popov VYu. New opportunities of medical therapy of patients with corneal-conjunctival xerosis. RMJ. Clinical Ophthalmology = RMZh. Klinicheskaya oftal’mologiya. 2016;17(1):39-46 (In Russ.).
  4. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276-283.  https://doi.org/10.1016/j.jtos.2017.05.008
  5. Belmonte C, Nichols JJ, Cox SM, Brock JA, Begley CG, Bereiter DA, Dartt DA, Galor A, Hamrah P, Ivanusic JJ, Jacobs DS, McNamara NA, Rosenblatt MI, Stapleton F, Wolffsohn JS. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15(3):404-437.  https://doi.org/10.1016/j.jtos.2017.05.002
  6. Baudouin C, Aragona P, Messmer EM, Tomlinson A, Calonge M, Boboridis KG, Akova YA, Geerling G, Labetoulle M, Rolando M. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11(4):246-258.  https://doi.org/10.1016/j.jtos.2013.07.003
  7. Messmer EM, Ahmad S, Benitez Del Castillo JM, Mrukwa-Kominek E, Rolando M, Vitovska O, Baudouin C; a panel of European dry eye disease experts. Management of inflammation in dry eye disease: Recommendations from a European panel of experts. Eur J Ophthalmol. 2023;33(3):1294-1307. https://doi.org/10.1177/11206721221141481
  8. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, Sullivan DA. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438-510.  https://doi.org/10.1016/j.jtos.2017.05.011
  9. De Oliveira RC, Wilson SE. Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol. 2019;13:1115-1122. https://doi.org/10.2147/OPTH.S184412
  10. Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124(11 suppl):S4-S13.  https://doi.org/10.1016/j.ophtha.2017.07.010
  11. Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benítez-del-Castillo J, Boboridis KG, Merayo-Lloves J, Rolando M, Labetoulle M. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100(3):300-306.  https://doi.org/10.1136/bjophthalmol-2015-307415
  12. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, Seo KY, Tauber J, Wakamatsu TH, Xu J, Wolffsohn JS, Craig JP. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575-628.  https://doi.org/10.1016/j.jtos.2017.05.006
  13. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75-92.  https://doi.org/10.1016/s1542-0124(12)70081-2
  14. Messmer EM. Pathophysiology of dry eye disease and novel therapeutic targets. Exp Eye Res. 2022;217:108944. https://doi.org/0.1016/j.exer.2022.108944
  15. Riks IA. Cyclosporine use in «dry eye» syndrome. Ophthalmol J. 2019; 12(3):75-82.  https://doi.org/10.17816/OV15853
  16. Brzhesky VV. Current opportunities of DED pathogenetically oriented therapy. Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2023;139(2): 77-85 (In Russ.). https://doi.org/10.17116/oftalma202313902177
  17. Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki P, Lazreg S, Pult H, Sullivan BD, Tomlinson A, Tong L, Villani E, Yoon KC, Jones L, Craig JP. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15(3):539-574.  https://doi.org/10.1016/j.jtos.2017.05.001
  18. Brzhesky VV, Maychuk DYu. New opportunities of immunosuppressive therapy in patients with DED. Oftal’mologicheskiye vedomosti. 2012;5(1):69-74. (In Russ.).
  19. Maychuk DYu. Cyclosporin in therapy of eye diseases. Oftal’mologicheskiy zhurnal (Odessa). 1996;(5-6):316-320. (In Russ.).
  20. Maychuk DYu, Moroz ZI, Kovshun EV. Experience of topical use of cyclosporin eye drops for keratoplasty. In: Novyye lekarstvennyye preparaty [New medicinal products]. M. 2000;26-29. (In Russ.).
  21. Maychuk DYu, Vakhov ES, Maychuk YuF. Use of liposomal cyclosporine eye drops — Cyclolip in treatment of inflammatory eye disease. In: Novyye lekarstvennyye preparaty [New medicinal products]. M. 2000;29-32. (In Russ.).
  22. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021023
  23. https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=84085fbe-9256-4b38-aa97-5bf19cddef10 
  24. Summary of Product characteristics Ikervis. https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis
  25. Summary of Product characteristics Verkazia. https://www.ema.europa.eu/en/medicines/human/EPAR/verkazia#authorisation-details-section
  26. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e17773be-92cc-463d-88c4-14756c919a5b
  27. Daull P, Amrane M, Ismail D, Georgiev G, Cwiklik L, Baudouin C, Leonardi A, Garhofer G, Garrigue JS. Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease. J Ocul Pharmacol Ther. 2020;36(6): 355-365.  https://doi.org/10.1089/jop.2020.0011
  28. Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012:604204. https://doi.org/10.1155/2012/604204
  29. Daull P, Lallemand F, Philips B, Lambert G, Buggage R, Garrigue JS. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Cornea. 2013;32(3): 345-354.  https://doi.org/10.1097/ICO.0b013e31825e83f4
  30. Baudouin C, Figueiredo FC, Messmer EM, Ismail D, Amrane M, Garrigue JS, Bonini S, Leonardi A. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27(5):520-530.  https://doi.org/10.5301/EJO.5000952
  31. Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue JS, Figueiredo FC, Baudouin C. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287-296.  https://doi.org/10.5301/ejo.5000779
  32. Pisella PJ, Labetoulle M, Doan S, Cochener-Lamard B, Amrane M, Ismail D, Creuzot-Garcher C, Baudouin C. Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. Clin Ophthalmol. 2018;12:289-299.  https://doi.org/10.2147/OPTH.S150957
  33. Labetoulle M, Leonardi A, Amrane M, Ismail D, Garrigue JS, Garhöfer G, de la Maza MS, Baudouin C. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study. Clin Ther. 2018;40(11):1894-1906. https://doi.org/10.1016/j.clinthera.2018.09.012
  34. Geerling G, Hamada S, Trocmé S, Ræder S, Chen X, Fassari C, Lanzl I; PERSPECTIVE study group. Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment. Ophthalmol Ther. 2022;11(3):1101-1117. https://doi.org/10.1007/s40123-022-00487-x
  35. Leonardi A, Messmer EM, Labetoulle M, Amrane M, Garrigue JS, Ismail D, Sainz-de-la-Maza M, Figueiredo FC, Baudouin C. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103(1):125-131.  https://doi.org/10.1136/bjophthalmol-2017-311801
  36. Kim S, Sook Hwang Y, Hyang Chung S. Efficacy of 0.1% cyclosporine eye drops in Sjögren syndrome dry eye. Acta Ophthalmol. 2021;99.  https://doi.org/10.1111/j.1755-3768.2020.0090
  37. Rouimi F, Bouillot A, Baudouin C, Labbé A. Ciclosporine A topique et risque de néoplasie de la surface oculaire [Topical cyclosporine A and risk of ocular surface neoplasia]. J Fr Ophtalmol. 2018;41(2):122-128 (In French). https://doi.org/10.1016/j.jfo.2017.09.005
  38. Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, Kim T, Mehta JS, Messmer EM, Pepose JS, Sangwan VS, Weiner AL, Wilson SE, Wolffsohn JS. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15(3):511-538.  https://doi.org/10.1016/j.jtos.2017.05.004
  39. Cheng X, Huang R, Huang S, Fan W, Yuan R, Wang X, Zhang X. Recent advances in ocular graft-versus-host disease. Front Immunol. 2023;14:1092108. https://doi.org/10.3389/fimmu.2023.1092108
  40. Cantú-Rodríguez OG, Vázquez-Mellado A, González-Treviño JL, Martínez-Garza DM, Gómez-De León A, Hawing-Zarate JA, Jaime-Pérez JC, Gutierrez-Aguirre CH, Garza-Acosta AC, Mancías-Guerra C, González-Llano O, González-Cantú GA, Herrera-Rojas MA, Sada-Ovalle I, Gómez-Almaguer D. Cyclosporine A for the Prevention of Ocular Graft versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Is Safe and Feasible. Acta Haematol. 2020;143(5):425-431.  https://doi.org/10.1159/000502405
  41. Tong L, Lim EWL, Yeo SWJ, Hou A, Linn YC, Ho A, Than H, Quek JKS, Hwang WYK, Lim FLWI, Lim L. Conjunctival T Cell Profile in Allogeneic Hematopoietic Stem Cell Transplant Patients after Instilling Topical Cyclosporine-A 0.1% Cationic Emulsion. Ophthalmol Ther. 2023;12(3):1547-1567. https://doi.org/10.1007/s40123-023-00686-0
  42. Grishina EE, Ageenkova OA. DED associated with chemotherapy of malignancies. In: VI Vserossiyskaya shkola oftal’mologa: Sb. nauch. tr. [VI All-Russian School of Ophthalmology: Collection of scientific works]. Ed. Egorov E.A. M. 2007;321-323. (In Russ.).
  43. Deshmukh R, Ting DSJ, Elsahn A, Mohammed I, Said DG, Dua HS. Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases. Br J Ophthalmol. 2022;106(8):1087-1092. https://doi.org/10.1136/bjophthalmol-2020-317907
  44. Chatterjee S, Agrawal D. Use of Topical Cyclosporine 0.1% in Therapeutic Penetrating Keratoplasty for Fungal Keratitis. Cornea. 2022;41(9):1116-1121. https://doi.org/10.1097/ICO.0000000000002827
  45. Saini M, Dhiman R, Dada T, Tandon R, Vanathi M. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye (Lond). 2015; 29(6):808-814.  https://doi.org/10.1038/eye.2015.40
  46. Boboridis KG, Konstas AGP. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. Expert Opin Pharmacother. 2018;19(9): 1027-1039. https://doi.org/10.1080/14656566.2018.1479742
  47. Periman LM, Mah FS, Karpecki PM. A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments. Clin Ophthalmol. 2020;14:4187-4200. https://doi.org/10.2147/OPTH.S279051
  48. Kim JG, An JH, Cho SY, Lee CE, Shim KY, Jun JH. Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications. J Ocul Pharmacol Ther. 2023;39(6):389-397.  https://doi.org/10.1089/jop.2022.018
  49. Labetoulle M, Leonardi A, Pisella PJ, Baudouin C. Ciclosporin A Cationic Emulsion 0.1% for the Management of Dry Eye Disease: Facts That Matter for Eye-Care Providers. Ocul Immunol Inflamm. 2023;31(8):1707-1715. https://doi.org/10.1080/09273948.2022.2088566
  50. Lin BW, Huang WL, Wang L, Chen ZM. Comparison of 0.025% FK-506, 0.05% Cyclosporin A, and 0.3% Sodium Hyaluronate Eye Drops for the Treatment of Botulinum Toxin B-Induced Mouse Dry Eye. J Ocul Pharmacol Ther. 2018;34(9):633-641.  https://doi.org/10.1089/jop.2018.0044
  51. Demiryay E, Yaylali V, Cetin EN, Yildirim C. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome. Eye Contact Lens. 2011;37(5): 312-315.  https://doi.org/10.1097/ICL.0b013e31822563be
  52. White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease. Clin Ophthalmol. 2020;14:875-883.  https://doi.org/10.2147/OPTH.S233194
  53. White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease. Clin Ophthalmol. 2020;14:931-938.  https://doi.org/10.2147/OPTH.S237832
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.